{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "XERS",
  "name": "Xeris Biopharma Holdings, Inc.",
  "url": "https://frontierpicks.com/dossiers/XERS/",
  "json_url": "https://frontierpicks.com/dossiers/XERS.json",
  "status": "HELD",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Xeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over three months because Recorlev sales rose 93% to $71.5 million in the third quarter and 2026 revenue guidance rose to $395–405 million. Preliminary fourth-quarter revenue, which the company gave on 8 January 2026 last year and is expected in early January 2027, shows whether that growth holds.",
  "invalidation_trigger": "A daily close below $10.46, the last close before the 2026-11-05 report, which would erase the post-earnings gain. The case would also break if fourth-quarter 2026 Recorlev revenue falls below the third quarter's $71.5 million, or 2026 total revenue comes in under $395 million.",
  "catalyst_date": "2026-11-17",
  "portfolio": {
    "status": "open",
    "opened": "2026-11-12",
    "closed": null,
    "return_pct": 0.4,
    "spy_return_pct": null,
    "vs_spx_pp": 0.7,
    "beat": null,
    "sold_on": null,
    "case": {
      "thesis": "Recorlev's sequential growth is quickening: $49.8 million, $56.8 million, then $71.5 million in Q3 2026 (+93% on the year), lifting total revenue 44% to $107.2 million at an 88% gross margin and adjusted EBITDA to $30.8 million. The Q4 guide assumes Recorlev adds only about $10 million after Q3's $14.7 million, and the 2030 outlook rose to more than $1 billion. Market value was about $3.0 billion at the 11 November 2026 close, about 7.7x the 2026 revenue guide.",
      "bought_on": {
        "kind": "results",
        "date": "2026-11-05",
        "text": "Q3 2026 results: total revenue rose 44% to $107.2 million, Recorlev rose 93% to $71.5 million, 2026 revenue guidance was raised to $395–405 million from $385–390 million and the 2030 revenue outlook to more than $1 billion from about $750 million."
      },
      "exit_when": [
        "Recorlev quarterly net revenue falls from the prior quarter (Q3 2026: $71.5 million, up from $56.8 million in Q2).",
        "2027 total revenue guidance below $475 million, under 20% growth on the 2026 guide of $395–405 million.",
        "A court ruling or settlement in the Torrent/Somerset ANDA case that allows generic levoketoconazole before 2032."
      ]
    },
    "changes": [
      {
        "session": "2026-11-12",
        "ticker": "XERS",
        "action": "buy",
        "fact": {
          "kind": "results",
          "date": "2026-11-05",
          "text": "Q3 2026 results: total revenue rose 44% to $107.2 million, Recorlev rose 93% to $71.5 million, 2026 revenue guidance was raised to $395–405 million from $385–390 million and the 2030 revenue outlook to more than $1 billion from about $750 million."
        }
      }
    ],
    "history": [],
    "url": "https://frontierpicks.com/portfolio/"
  },
  "pick": {
    "status": "open",
    "opened": "2026-11-12",
    "closed": null,
    "beat": null
  },
  "themes": [
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "caveats": [
    {
      "claim": "Recorlev faces Paragraph IV generic challenges from Torrent, Somerset, Sandoz, Zydus and Novitium in the District of New Jersey; a bench trial is tentatively set for November 2028.",
      "source": "Form 10-Q for the third quarter of 2026",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Four customers accounted for 98% of Xeris's gross product revenue in the first nine months of 2026.",
      "source": "Form 10-Q for the third quarter of 2026",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Several Xeris officers sell shares under pre-arranged Rule 10b5-1 trading plans, so sales appear in Form 4 filings on a recurring monthly schedule.",
      "source": "SEC Form 4 filings dated 2026-10-02, 2026-11-04 and 2026-11-06",
      "as_of": "2026-11-06"
    }
  ],
  "source_links": [
    {
      "title": "Xeris Biopharma Holdings, Inc. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001867096/000186709626000114/exh991q32026earningsrelease.htm",
      "date": "2026-11-05"
    },
    {
      "title": "Xeris Biopharma Holdings, Inc. - Form 10-Q - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001867096/000186709626000117/xers-20260930.htm",
      "date": null
    },
    {
      "title": "Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2026/11/05/xeris-biopharma-xers-q3-2026-earnings-call-transcript/",
      "date": "2026-11-05"
    },
    {
      "title": "Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $18.00",
      "url": "https://www.dailypolitical.com/2026/11/11/xeris-biopharma-nasdaqxers-price-target-raised-to-18-00.html",
      "date": "2026-11-11"
    },
    {
      "title": "Xeris Biopharma Holdings, Inc. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/pressreleaseissuedbyxerisb.htm",
      "date": null
    },
    {
      "title": "Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance",
      "url": "https://www.businesswire.com/news/home/20260302553712/en/Xeris-Biopharma-Reports-Record-Performance-for-Fourth-Quarter-and-Full-Year-2025-and-Provides-Full-Year-2026-Guidance",
      "date": "2026-03-02"
    },
    {
      "title": "Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports",
      "url": "https://in.investing.com/news/stock-market-news/lundbeck-approaches-xeris-biopharma-over-potential-takeover-bloomberg-reports-5611539",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 total revenue was $107.2 million, up 44%. Recorlev was $71.5 million (up 93%), Gvoke $21.7 million (down 14%, including a one-time $4 million adjustment) and Keveyis $13.0 million (up 9%).",
      "source": "Q3 2026 earnings release, Form 8-K exhibit 99.1",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Third-quarter net income was $11.3 million versus $0.6 million a year earlier. Adjusted EBITDA rose $13.3 million to $30.8 million, and selling, general and administrative expense rose 38% to $64.1 million.",
      "source": "Q3 2026 earnings release, Form 8-K exhibit 99.1",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Full-year 2026 total revenue guidance was raised to $395–405 million from $385–390 million. The 2030 revenue outlook rose to more than $1 billion from about $750 million.",
      "source": "Q3 2026 earnings release, Form 8-K exhibit 99.1",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Oppenheimer raised its target to $21 from $18 (Outperform), HC Wainwright to $18 from $10 (Buy) and Piper Sandler to $12 from $8 (Neutral).",
      "source": "Benzinga analyst headlines, 2026-11-06",
      "as_of": "2026-11-06"
    },
    {
      "claim": "Barclays kept its Overweight rating on Xeris and raised its price target to $18 from $14.",
      "source": "Benzinga analyst headline; Daily Political, 2026-11-11",
      "as_of": "2026-11-11"
    },
    {
      "claim": "Kevin McCulloch sold 25,000 shares at $12.49 on 2026-11-05 under a Rule 10b5-1 plan; on 2026-11-02 McCulloch, Beth Hecht and Steven Pieper sold 45,000 shares combined at $10.23 under such plans.",
      "source": "SEC Form 4 filings dated 2026-11-04 and 2026-11-06",
      "as_of": "2026-11-06"
    },
    {
      "claim": "On 2026-01-08 Xeris said 2025 total revenue would be about $292 million, above its $285–290 million guidance; the full-year report and first 2026 guidance of $375–390 million followed on 2026-03-02.",
      "source": "Xeris 8-K press release, 2026-01-08; full-year 2025 results release, 2026-03-02",
      "as_of": "2026-03-02"
    },
    {
      "claim": "Cash and short-term investments were $131 million and long-term debt $190 million at 2026-09-30; the 8.00% 2028 convertible notes were fully retired on 2026-07-15.",
      "source": "Q3 2026 Form 10-Q; Q3 2026 earnings release",
      "as_of": "2026-09-30"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-15",
    "business": "Xeris Biopharma sells three prescription drugs in the US: Recorlev for Cushing's syndrome, Gvoke ready-to-use glucagon for severe low blood sugar, and Keveyis for primary periodic paralysis. It earns money on product sales through a small number of distributors and pharmacies; revenue was $107 million in the quarter to 2026-09-30.",
    "change": {
      "now": "On 2026-11-05 Xeris raised 2026 revenue guidance to $395–405 million from $385–390 million and its 2030 outlook to more than $1 billion, after third-quarter Recorlev revenue rose 93% to $71.5 million.",
      "next": "Operating margin rose to 15.8% in the third quarter from 9.0% a year earlier and gross margin to 88.4%, while selling, general and administrative expense rose 38% to $64.1 million to fund the larger Recorlev sales team.",
      "linked": "Corcept Therapeutics (CORT), which also treats Cushing's syndrome patients, competes for the same referrals; Amphastar (AMPH), maker of Baqsimi, competes with Gvoke, whose sales fell 14% in the quarter."
    },
    "priced_in": "At the 2026-11-13 close (filed figures to 2026-11-05) the shares trade at 8.4 times sales and 66.3 times operating profit, for an enterprise value of $3,102 million; the P/E is not meaningful and P/B is 62.4. That holds only if revenue keeps growing near the 44% of the latest filed quarter while the operating margin widens from 15.8%.",
    "links": {
      "customers": [],
      "suppliers": [],
      "competitors": [
        {
          "ticker": "CORT",
          "url": "https://frontierpicks.com/dossiers/CORT/"
        },
        {
          "ticker": "AMPH",
          "url": null
        }
      ]
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "value_musd": 107.2,
              "yoy_pct": 44.2
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "value_musd": 92.1,
              "yoy_pct": 28.7
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "value_musd": 83.1,
              "yoy_pct": 38.3
            },
            {
              "end": "2025-12-31",
              "filed": "2026-03-02",
              "restated": null,
              "value_musd": 85.8,
              "yoy_pct": 42.8
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-06",
              "restated": null,
              "value_musd": 74.4,
              "yoy_pct": 37.1
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-07",
              "restated": null,
              "value_musd": 71.5,
              "yoy_pct": 48.8
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "pct": 88.4
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "pct": 86.4
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "pct": 87.3
            },
            {
              "end": "2025-12-31",
              "filed": "2026-03-02",
              "restated": null,
              "pct": 87.2
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-06",
              "restated": null,
              "pct": 85.2
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-07",
              "restated": null,
              "pct": 83.4
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "pct": 15.8
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "pct": 5.6
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "pct": 9.5
            },
            {
              "end": "2025-12-31",
              "filed": "2026-03-02",
              "restated": null,
              "pct": 19.5
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-06",
              "restated": null,
              "pct": 9
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-07",
              "restated": null,
              "pct": 6.3
            }
          ]
        },
        "pretax_income": {
          "status": "not reported"
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "four_quarters_end": "2026-09-30",
          "value_musd": 11.3,
          "four_quarters_musd": -6.5
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": 73.6
        },
        "capital_spending": {
          "status": "not reported"
        },
        "free_cash_flow": {
          "status": "not available"
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "base_end": "2025-09-30",
          "pct": 6.9
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 131.1
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 189.7,
          "composition": "long-term debt"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": -58.6
        },
        "deferred_revenue": {
          "status": "not reported"
        },
        "backlog": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 6.2,
          "yoy_pct": null
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 68.6
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 76.9
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 48.8
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "value_musd": 3043.8
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "value_musd": 3102.4
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "multiple": 8.4
        },
        "ev_ebit": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "multiple": 66.3
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "multiple": 62.4
        },
        "fcf_yield": {
          "status": "not available"
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": 4.39,
      "days_to_cover": 3.3,
      "change_pct": 11.5
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 1678996.4,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 0,
          "sold_usd": 5830808.43,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\n\nXeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over the next three months. The reason is Recorlev, the company's Cushing's syndrome drug: its sales rose 93% to $71.5 million in the third quarter, and on 2026-11-05 management raised 2026 revenue guidance to $395–405 million. The first test comes in early January 2027, when the company has in the past given preliminary fourth-quarter revenue. It did so on 2026-01-08 for 2025, ahead of its full-year report on 2026-03-02.\n\nThe shares closed at $16.66 on 2026-11-13, a new closing high and 1.3% below the 52-week intraday high of $16.88 set on 2026-11-12. They are up 95.5% over three months from the $8.52 close on 2026-08-17. At that price the market already pays 8.4 times sales for the business. The close sits above Piper Sandler's $12 target, just under the $18 targets from HC Wainwright (2026-11-06) and Barclays (2026-11-11), and below Oppenheimer's $21 (2026-11-06).\n\nThe rating is Medium because the gain rests on reported results, a guidance raise and four analyst target increases since the report. Three things hold the odds below High. One drug carries the growth. Insiders keep selling under pre-arranged plans. The valuation now leaves little room for a soft fourth quarter.\n\n## Bull Case\n- **Recorlev growth sped up.** Recorlev net revenue was $71.5 million in the quarter ended 2026-09-30, up 93% from a year earlier, according to the 2026-11-05 earnings release. On the 2026-11-05 call, management credited the expanded sales team with record referrals and new patient starts.\n- **Guidance rose above the estimate.** On 2026-11-05 the company raised 2026 total revenue guidance to $395–405 million, from $385–390 million. Benzinga put the consensus estimate at $387.665 million when the report came out. The guide had started the year at $375–390 million on 2026-03-02.\n- **The quarter was profitable.** Net income was $11.3 million, against $0.6 million a year earlier, according to the release. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose $13.3 million to $30.8 million. Filed figures show gross margin of 88.4% and operating margin of 15.8%, against 85.2% and 9.0% a year earlier.\n- **The long-range outlook moved up.** On 2026-11-05 the company raised its 2030 revenue outlook to more than $1 billion, from about $750 million. It said Recorlev could reach nearly $1 billion in annual net revenue three to four years sooner than it had expected.\n- **Analysts raised targets after the report.** Oppenheimer raised its target to $21 from $18 (Outperform) and HC Wainwright to $18 from $10 (Buy) on 2026-11-06. Barclays kept its Overweight rating and raised its target to $18 from $14 on 2026-11-11, according to Benzinga and Daily Political.\n- **The company has beaten its own numbers before.** On 2026-01-08 Xeris said 2025 revenue would be about $292 million, above its $285–290 million guidance, and the 2026-03-02 report confirmed it.\n- **A buyer has shown interest.** On 2026-09-29 Investing.com carried a Bloomberg report that H. Lundbeck was working with advisers on a possible acquisition, with talks described as preliminary. A Xeris spokeswoman said the company is not for sale.\n\n## Bear Case\n- **One drug carries the growth.** Recorlev was $71.5 million of $106.3 million in third-quarter net product revenue, according to the release. Gvoke fell 14% to $21.7 million, including a one-time $4 million adjustment. Keveyis rose 9% to $13.0 million.\n- **Costs are rising with sales.** Selling, general and administrative expense rose 38% to $64.1 million in the third quarter, and 32% to $178.3 million over nine months, according to the release. Net income over the four quarters to 2026-09-30 was a loss of $6.5 million, according to filed figures.\n- **The price asks a lot.** At the 2026-11-13 close the shares trade at 66.3 times operating profit and 62.4 times book value, on filed figures to 2026-11-05. Equity was $49 million at 2026-09-30.\n- **Generic challenges are pending.** Torrent, Somerset, Sandoz, Zydus and Novitium have filed Paragraph IV challenges to Recorlev patents in the District of New Jersey, according to the third-quarter 10-Q. A bench trial is tentatively set for November 2028.\n- **One post-report target sits below the price.** Piper Sandler raised its target to $12 from $8 on 2026-11-06 and kept a Neutral rating. The 2026-11-13 close of $16.66 is 39% above it.\n- **Insiders sell every month.** SEC Form 4 filings show Kevin McCulloch sold 25,000 shares at $12.49 on 2026-11-05. On 2026-11-02 McCulloch sold 15,000, Beth Hecht 25,000 and Steven Pieper 5,000 shares at $10.23, after similar sales at $9.41 on 2026-10-01. All were made under Rule 10b5-1 plans, which are pre-arranged trading plans.\n- **Debt exceeds cash.** Cash and short-term investments were $131 million and long-term debt $190 million at 2026-09-30, according to the 10-Q. The diluted share count rose 6.9% from a year earlier.\n\n## Setup & Price Structure\nThe shares rose on the 2026-11-05 report in a session when the S&P 500 fell 3.3% and the Nasdaq 4.5%, according to Benzinga. Adjusted daily closes then show $15.20 on 2026-11-06, $15.86 on 2026-11-09 and $15.83 on 2026-11-10. New closing highs followed: $16.52 on 2026-11-11, $16.65 on 2026-11-12 and $16.66 on 2026-11-13.\n\nAs of the 2026-11-13 close, the 50-day moving average was $10.40 and the 200-day moving average $7.83. The shares have not pulled back since the report, so the gain has not been tested. The 50-day average sits close to where the shares traded before the report. The 52-week closing low was $5.29 on 2026-03-24, so the shares have roughly tripled from it.\n\nA common market view is that a stock which nearly doubles in three months gives part of it back; tests on ten years of US stocks have found no reliable effect so far after rises of that size. The company's next scheduled events are the 2026-11-17 and 2026-12-01 conference fireside chats, the start of the Phase 3 trial of XP-8121 guided for year-end 2026, and the January preliminary revenue update the company gave in 2026.\n\n## Catalyst Calendar\n\n- **2026-11-17:** Fireside chat at the Jefferies London Healthcare Conference, webcast live. It is the first scheduled public appearance since the 2026-11-05 report and may add detail on Recorlev referrals and spending.\n- **2026-12-01:** Fireside chat at the Piper Sandler Healthcare Conference in New York, webcast live. It gives management a second public setting to discuss Recorlev demand and 2027 spending, for which no guidance has been given.\n- **~2026-12-31 (est.):** Start of Cornerstone, the pivotal Phase 3 trial of XP-8121, guided for year-end 2026. It shows whether the next growth product enters late-stage testing on schedule, with topline results expected in late 2028.\n- **~2027-01-07 (est.):** Preliminary fourth-quarter and full-year 2026 revenue, following the 2026-01-08 precedent. It is the first read on whether Recorlev grows from the third quarter's $71.5 million and whether 2026 revenue lands inside the $395–405 million guidance.\n- **~2027-03-01 (est.):** Full fourth-quarter and full-year 2026 results with 2027 guidance. It sets the 2027 revenue and expense outlook, which shows whether growth near 2026's pace supports the current valuation.\n\n## What Would Change Our Mind\n\nA daily close below $10.46, the last close before the 2026-11-05 report, which would erase the post-earnings gain. The case would also break if fourth-quarter 2026 Recorlev revenue falls below the third quarter's $71.5 million, or 2026 total revenue comes in under $395 million.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Recorlev growth slows, leaving a company whose other two products contribute far less revenue. Confirmed by: Fourth-quarter 2026 Recorlev revenue below the third quarter's $71.5 million, or 2026 total revenue under $395 million.\n- 2027 guidance shows growth slowing sharply from 2026. Confirmed by: 2027 total revenue guidance below $475 million, under 20% growth on the 2026 guide of $395–405 million.\n- Generic Recorlev reaches the market earlier than the company expects. Confirmed by: A court ruling or settlement in the Torrent/Somerset case in the District of New Jersey that allows generic levoketoconazole before 2032.\n- Sales-force spending grows faster than revenue and earnings progress stalls. Confirmed by: Adjusted EBITDA below the third quarter's $30.8 million, or 2027 expense guidance that outpaces revenue growth.\n- The share price runs ahead of what analysts will underwrite. Confirmed by: A downgrade or target cut from Oppenheimer, HC Wainwright, Barclays or Piper Sandler, or insider sales stepping up beyond the recurring 10b5-1 schedule.\n- The balance sheet needs new capital while debt exceeds cash. Confirmed by: New equity or convertible issuance, or a refinancing of the Hayfin loan due 2029-03-05 on worse terms.\n\n## Correlation Notes\nXeris is grouped with rare-disease drug makers such as Viridian Therapeutics (VRDN), Disc Medicine (IRON), Liquidia (LQDA) and Eton Pharmaceuticals (ETON). Its recent move has followed its own results more than the group or the market: it rose on 2026-11-05, a session in which the Nasdaq fell 4.5%, according to Benzinga. Unlike most of those peers, Xeris sells three approved products and reported a profit in the third quarter of 2026. Its shared exposures are mid-cap biotech sentiment and buyers' appetite for commercial-stage specialty drug makers, which the 2026-09-29 Lundbeck report put in focus. In Cushing's syndrome it competes with Corcept Therapeutics (CORT); in severe low blood sugar Gvoke competes with Amphastar's (AMPH) Baqsimi. If the peer group cools, the case rests on the Recorlev numbers.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-15T12:22:50+00:00",
  "last_synthesized": "2026-11-15",
  "date_modified": "2026-11-15",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}